此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

2018年9月28日 更新者:Marvao Medical

Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

A U.S. multi-centre post approval registry to analyse the CRBSI rate in patients with the NexSite HD Catheter for long term vascular access for hemodialysis.

研究概览

地位

完全的

详细说明

This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only.

The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed.

Secondary endpoints for the study are

  • Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis.
  • Healing of catheter exit site
  • Tunnel Infections
  • Exit site infections
  • Early non-infectious complications associated with CVCs
  • Late non-infectious complications associated with Central Venous Catheters

研究类型

介入性

注册 (实际的)

120

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • North Carolina
      • Greenville、North Carolina、美国、27834
        • Eastern Nephrology Associates
      • New Bern、North Carolina、美国、28542
        • Eastern Nephology Associates
      • Raleigh、North Carolina、美国、27610
        • Capital Nephrology Associates
    • South Carolina
      • Orangeburg、South Carolina、美国、29118
        • South Carolina Nephrology and Hypertension Center Inc
    • Texas
      • Lubbock、Texas、美国、79416
        • Lubbock Vascular Access Centre
      • San Antonio、Texas、美国、78215
        • Renal Associates

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. The patient shall be 18 - 80 years old.
  2. The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.
  3. The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.
  4. The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.
  5. The patient receives the catheter via the internal jugular or subclavian vein.
  6. All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.

Exclusion Criteria:

  1. The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.
  2. The patient has a confirmed or suspected infection, bacteraemia or septicaemia.
  3. The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.
  4. The patient is known or suspected to have allergies to the materials used in the construction of the device.
  5. The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.
  6. The patient has received radiation treatment at the proposed catheter placement site.
  7. The patient has severe chronic obstructive lung disease.
  8. The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.
  9. The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device [IUD], birth control pills, or spermicidal gel with diaphragm or condom)
  10. The patient has another indwelling catheter.
  11. The patient has non-healing diabetic foot ulcers.
  12. The patient did not give informed consent.
  13. The patient would be unavailable for follow-up.
  14. The patient is a permanent nursing home resident.
  15. The proposed access site is not the internal jugular or subclavian vein.
  16. The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.
  17. Any other condition that the Investigator believes should exclude the patient from the study.
  18. The patient does not have English or Spanish as their first language.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:NexSite HD Patients
NexSite HD patient catheter device placement
Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.
大体时间:Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with a confirmed CRBSI for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)

次要结果测量

结果测量
措施说明
大体时间
Number of participants with adverse events associated with device placement and use.
大体时间:Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with adverse events associated with device placement and for the duration of catheter use or to 180 days post device placement.
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with unhealed catheter exit sites
大体时间:Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with unhealed exit sites for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with tunnel infection as an adverse event
大体时间:Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with a tunnel infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with exit site infection as an adverse event
大体时间:Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with a exit site infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.
大体时间:1 day of device placement
Number of participants with non-infectious catheter complications within one day of placement.
1 day of device placement
Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.
大体时间:Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with late non infectious complications for the duration of catheter use or to 180 days post device placement (whichever occurs first).
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jeffrey G Hoggard, MD、Capital Nephrology Associates

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年4月1日

初级完成 (实际的)

2017年9月1日

研究完成 (实际的)

2018年7月1日

研究注册日期

首次提交

2015年5月18日

首先提交符合 QC 标准的

2015年5月22日

首次发布 (估计)

2015年5月25日

研究记录更新

最后更新发布 (实际的)

2018年10月1日

上次提交的符合 QC 标准的更新

2018年9月28日

最后验证

2018年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

NexSite HD Patients的临床试验

订阅